Concepedia

Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530

Silvia L. Locatelli, Giuseppa Careddu, Simone Serio, Francesca Maria Consonni, Akihiro Maeda, Srikant Viswanadha, Swaroop Vakkalanka, Luca Castagna, Armando Santoro, Paola Allavena,

Clinical Cancer Research · 2018 · 77 citations · 24 references

DOI

Abstract

Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat patients with Hodgkin lymphoma.

References

24

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello et al. · New England Journal of Medicine · 2014 · 3.5K citations · Full text

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

Oscar R. Colegio, Ngoc-Quynh Chu, Alison L. Szabo et al. · Nature · 2014 · 2.8K citations · Full text

, , +6

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

Anas Younes, Ajay K. Gopal, Scott E. Smith et al. · Journal of Clinical Oncology · 2012 · 1.5K citations · Full text

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

Anas Younes, Nancy L. Bartlett, John P. Leonard et al. · New England Journal of Medicine · 2010 · 1.3K citations · Full text

Pyruvate Kinase M2 Regulates Hif-1α Activity and IL-1β Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages

Eva M. Pålsson‐McDermott, Annie M. Curtis, Gautam Goel et al. · Cell Metabolism · 2015 · 1.3K citations · Full text

, , +10